CO6430497A2 - Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Info

Publication number
CO6430497A2
CO6430497A2 CO11117849A CO11117849A CO6430497A2 CO 6430497 A2 CO6430497 A2 CO 6430497A2 CO 11117849 A CO11117849 A CO 11117849A CO 11117849 A CO11117849 A CO 11117849A CO 6430497 A2 CO6430497 A2 CO 6430497A2
Authority
CO
Colombia
Prior art keywords
follow
treatment
biomarkers
methyl
additional
Prior art date
Application number
CO11117849A
Other languages
English (en)
Spanish (es)
Inventor
Tokuzo Arao
Kanae Kudo
Kazuhiko Nakagawa
Nishio Kazuto
Original Assignee
Boheringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6430497(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boheringer Ingelheim Internat Gmbh filed Critical Boheringer Ingelheim Internat Gmbh
Publication of CO6430497A2 publication Critical patent/CO6430497A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO11117849A 2009-03-12 2011-09-12 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento CO6430497A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
CO6430497A2 true CO6430497A2 (es) 2012-04-30

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11117849A CO6430497A2 (es) 2009-03-12 2011-09-12 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (https=)
EP (1) EP2406628A1 (https=)
JP (1) JP5667581B2 (https=)
KR (1) KR20110137307A (https=)
CN (1) CN102334030A (https=)
AR (1) AR076113A1 (https=)
AU (1) AU2010223256B2 (https=)
BR (1) BRPI1011688A2 (https=)
CA (1) CA2755055A1 (https=)
CL (1) CL2011002260A1 (https=)
CO (1) CO6430497A2 (https=)
EA (1) EA201101300A1 (https=)
EC (1) ECSP11011323A (https=)
IL (1) IL214747A0 (https=)
MA (1) MA33120B1 (https=)
MX (1) MX2011009482A (https=)
NZ (1) NZ594843A (https=)
PE (1) PE20120592A1 (https=)
SG (1) SG174324A1 (https=)
TN (1) TN2011000457A1 (https=)
TW (1) TW201100802A (https=)
UA (1) UA107789C2 (https=)
UY (1) UY32482A (https=)
WO (1) WO2010103058A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104590C2 (ru) * 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
JP2009534666A (ja) 2006-04-18 2009-09-24 ウェルスタット バイオロジックス コーポレイション 循環内皮細胞の検出
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
AU2007293280A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
US20100234381A1 (en) 2007-04-13 2010-09-16 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer

Also Published As

Publication number Publication date
WO2010103058A1 (en) 2010-09-16
UY32482A (es) 2010-10-29
CN102334030A (zh) 2012-01-25
AU2010223256A1 (en) 2011-09-15
US20100233705A1 (en) 2010-09-16
EA201101300A1 (ru) 2012-04-30
IL214747A0 (en) 2011-11-30
JP2012520446A (ja) 2012-09-06
NZ594843A (en) 2014-03-28
BRPI1011688A2 (pt) 2016-03-22
EP2406628A1 (en) 2012-01-18
TN2011000457A1 (en) 2013-03-27
ECSP11011323A (es) 2011-10-31
SG174324A1 (en) 2011-10-28
CA2755055A1 (en) 2010-09-16
TW201100802A (en) 2011-01-01
JP5667581B2 (ja) 2015-02-12
AR076113A1 (es) 2011-05-18
CL2011002260A1 (es) 2012-03-23
US8802384B2 (en) 2014-08-12
UA107789C2 (en) 2015-02-25
KR20110137307A (ko) 2011-12-22
PE20120592A1 (es) 2012-06-09
MA33120B1 (fr) 2012-03-01
MX2011009482A (es) 2011-09-27
AU2010223256B2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
HUE057440T2 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
WO2012176172A3 (en) Combination therapy with psd-95 inhibitor for ischemia
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
PY1330684A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.

Legal Events

Date Code Title Description
FC Application refused